The role of HIFs in ischemia-reperfusion injury

Neil J Howell\(^1\)
Daniel A Tennant\(^2\)

\(^1\)Department of Cardiothoracic Surgery, University Hospital Birmingham, Edgbaston, Birmingham, UK; \(^2\)College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

Correspondence: Daniel A Tennant
College of Medical and Dental Sciences
University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Tel +44 121 4148651
Email d.tennant@bham.ac.uk

Neil J Howell
Department of Cardiothoracic Surgery,
University Hospital Birmingham,
Edgbaston, Birmingham, B15 2TH, UK
Email n.j.howell@me.com

Abstract: The reduction or cessation of the blood supply to an organ results in tissue ischemia. Ischemia can cause significant tissue damage, and is observed as a result of a thrombosis, as part of a disease process, and during surgery. However, the restoration of the blood supply often causes more damage to the tissue than the ischemic episode itself. Research is therefore focused on identifying the cellular pathways involved in the protection of organs from the damage incurred by this process of ischemia reperfusion (I/R). The hypoxia-inducible factors (HIFs) are a family of heterodimeric transcription factors that are stabilized during ischemia. The genes that are expressed downstream of HIF activity enhance oxygen-independent ATP generation, cell survival, and angiogenesis, amongst other phenotypes. They are, therefore, important factors in the protection of tissues from I/R injury. Interestingly, a number of the mechanisms already known to induce organ protection against I/R injury, including preconditioning, postconditioning, and activation of signaling pathways such as adenosine receptor signaling, converge on the HIF system. This review describes the evidence for HIFs playing a role in I/R protection mediated by these factors, highlights areas that require further study, and discuss whether HIFs themselves are good therapeutic targets for protecting tissues from I/R injury.

Keywords: hypoxia, adenosine, pre-conditioning, post-conditioning

Introduction

Ischemia, defined as an inadequate blood supply to an organ or part of the body,\(^1\) is a considerable clinical problem. It is observed in a number of chronic diseases including cardiovascular disease and diabetes, acute events such as stroke or myocardial infarctions, and during planned clinical procedures like organ transplantation and general surgery. Ischemia leads to a reduction in the supply of nutrients and oxygen as well as the removal of waste products from a tissue, and in doing this can lead to irreversible tissue damage and death.

Arguably more important is the subsequent reperfusion of the tissue or organ. Upon resumption of a normal blood supply, oxygen and nutrients flood back into the tissue. This can result in considerable damage to both the tissue in question and, depending on the scale of the ischemic insult, the rest of the body. If a severe ischemic episode has resulted in extensive necrotic damage, a wave of toxic cellular products can be released into the bloodstream upon reperfusion that, in the worst circumstances, can result in the death of the patient. However, even in acute ischemic events where this does not happen, the rush of nutrients and oxygen into the tissue can cause significant tissue damage, mainly through reactive oxygen species (ROS)-mediated oxidative damage of proteins, DNA, and lipids throughout the tissue.\(^2,3\)
The objective of much research in this area is to find means of reducing infarct size and thereby preserving tissue function after ischemia–reperfusion (I/R) injury. This has involved the investigation of means of inducing a protective state in the tissue both before and after the ischemic insult. Although studies over many years have demonstrated the efficacy of a number of agents in eliciting protection of various organs from I/R injury, most often, this demonstration has not led to the agent becoming an integral part of clinical practice. This may well be because we do not yet fully understand the intracellular signaling pathways that are required to invoke protection and, therefore, cannot design agents that can specifically target these pathways without off-target effects.

This review will discuss the evidence suggesting that the family of hypoxia-inducible factor (HIF) transcription factors may well represent such a target. Data from studies of methods of protecting tissues from ischemia suggest that HIFs may play a central role in mediating cellular protection. Future research strategies to specifically define how HIFs are best activated by either preconditioning (PreC) or postconditioning (PostC) approaches to generate a protected state may well lead to novel efficacious therapies to alleviate the clinical problems associated with I/R injury.

Control of the HIF transcription factors

The HIFs are heterodimeric transcription factors composed of an alpha and beta subunit. The beta subunit is considered to be constitutively expressed, while the alpha subunit is subject to a highly efficient oxygen-dependent system of control. There are three alpha subunits of HIF, of which 1α and 2α are the best described. Overall regulation of expression of the alpha subunits is through oxygen-induced proteolytic degradation, which gives a high degree of temporal control over the hypoxic response. Although stable under acute hypoxic conditions, alpha subunits are rapidly degraded in normoxia through the hydroxylation of target prolyl residues (P402 and P564 in human HIF1α) by prolyl hydroxylase enzymes (PHD1–3, encoded by the EGLN1-3 genes). These hydroxyprolyl residues are then recognized by the von Hippel–Lindau (pVHL) E3 ubiquitin ligase, which polyubiquitylates the HIFα subunit, targeting it for proteasomal degradation (Figure 1). This system provides exquisite control over the expression and activity of the HIF transcription factors, allowing them to be rapidly and reversibly upregulated upon reduction of the environmental oxygen.

The PHD enzymes, which represent the oxygen sensors in this system, are 2-oxoglutarate-dependent dioxygenases, which use 2-oxoglutarate (alpha-ketoglutarate) and oxygen to hydroxylate target substrates. They are, therefore, less active in low-oxygen (and presumably low-2-oxoglutarate) environments, such as during ischemia. Although HIF-independent roles for the PHD enzymes are becoming clearer, their most understood role is through the regulation of the HIF transcription factors. PHD2 has been shown as the major hydroxylase involved in regulating HIF1α stability, while PHD1 and 3 activities have both been correlated with HIF2α stability. During ischemic conditions, where PHDs are less active, HIFα subunits are rapidly stabilized, leading to the expression of the HIF-induced transcriptome. Interestingly, PHD2 and 3 are both transcriptional targets of HIF1, providing a HIF1-specific negative feedback loop (PHD2 and 3 have not been shown as HIF2 target genes) where hypoxia-induced HIF1 activity leads to increased PHD2 and 3 levels and, as a result, decreased HIF1α (and potentially HIF2α) expression.

Importantly, in terms of relevance to I/R injury, conditions that increase ROS generation, such as reoxygenation, have been shown to result in a longer-term stabilization of HIF1α, thereby inducing a prolonged hypoxic phenotype in reperfused cells. The mechanism by which this occurs has been suggested as the oxidative inactivation of the non-heme iron catalytic site of the PHD enzymes, although a further study suggested that the active site of the PHDs may not be accessible by ROS.

Other signaling pathways are also known to increase HIF1α protein expression independently of oxygen tension. Activation of AKT has been shown to increase HIF1α expression in normoxic conditions (Figure 1). The downstream pathway involved in this regulation appears to be through activation of mechanistic target of rapamycin (mTOR) also known as FKBP12 rapamycin-associated protein. mTOR and mitogen-activated protein kinases (MAPKs) can both phosphorylate 4E-BP1 to permit efficient cap-dependent translation of HIF1α messenger ribonucleic acid (mRNA). In ischemia, general translation is shut down through mechanisms including nutrient-sensitive inhibition of mTOR to conserve adenosine triphosphate (ATP) levels. However, cap-independent translation of some mRNA species, including HIF1 and 2α, is conserved. As previously mentioned, mTOR acts as a nutrient sensor – it is able to sense intracellular concentrations of the amino acids leucine and glutamine, thereby linking nutrient availability with anabolic processes. Other metabolic alterations that occur in ischemia are also capable of signaling to alter cellular phenotype. Succinate, a tricarboxylic acid cycle...
HIFs and ischemia reperfusion

A metabolite is often found at considerably higher concentrations in ischemic tissue, and it is a well-described inhibitor of the PHD enzymes, leading to HIFα stabilization (Figure 1). MAPK activity has also been shown to be required for the transactivational activity of HIF1 and 2. MAPKs are a large family of protein kinases consisting of three main groups: extracellular signal-regulated kinases; p38 MAPKs; and c-Jun N-terminal kinases. They are activated in response to diverse stimuli including growth factor signaling, cellular and environmental stress, and inflammatory cues. Once activated, members of this family have been shown to phosphorylate HIF1α, leading to enhanced binding of the coactivator p300/CBP-binding protein (Figure 1), although other independent pathways have also been suggested.

Hence, although oxygen tension is the most potent modulator of HIFα stability, there are many diverse means of altering HIF activity that can occur in ischemic and reperfused tissues. Many of these stabilization stimuli are downstream of signaling pathways that are known to be important in the protection of tissues from I/R injury and, therefore, provide some evidence, albeit indirect, for an important role for HIF in protection.

The effect of HIF stabilization on I/R injury

HIF1α was originally identified as a hypoxia-inducible nuclear factor that binds the EPO gene locus and induced its expression. Its gene targets have since been extensively characterized by a number of groups, and the hypoxia responsive elements (HREs) to which HIFs bind have been identified in numerous gene loci. More recently, it has been suggested that HIF1 may also have more wide-ranging effects on the ischemic transcriptome through its influence on promoter-bound RNA polymerase II, even at loci without associated HREs. HIF2α, also known as endothelial PAS protein 1 was cloned in 1997 by a number of groups. Although its regulation is less well-described than that of HIF1α, it also binds to HRE sequences and transactivates its target genes. Although HIF1α

Figure 1 The control of HIF expression and activity by factors involved in ischemic signaling.

Notes: HIFα expression is directly regulated by oxygen-dependent PHD enzymes that hydroxylate it in two positions for recognition by the pVHL E3 ubiquitin ligase, which targets HIFα for proteasomal degradation. PHD activity can be further controlled by changes in ROS and succinate levels, both of which are increased through mitochondrial dysfunction during ischemia. Further regulation of expression is performed through MAPK- and mTOR-mediated control of mRNA translation. Receptor tyrosine kinase signaling can increase HIF expression and activity through mTOR and MAPK signaling, while both the adenosine receptors 2A/B and cellular stresses can increase HIF activity through MAPK activation. MAPK-mediated phosphorylation of HIF1α is necessary for efficient transactivation of its target genes by enhancing the interaction with p300/CBP.

Abbreviations: α-KG, α-ketoglutarate; A2A/B, adenosine receptors 2A/B; ADORA2A, gene encoding A2A receptor; CD73, the membrane-bound extracellular 5′-nucleotidase; eTC, electron transport chain; Gs, stimulatory G protein; HIF, hypoxia-inducible factor; MAPK, mitogen-activated protein kinase; mTOR, mechanistic target of rapamycin; P, phosphorylated peptide residue; p300/CBP, p300/cyclic AMP adenosine monophosphate; PHD, HIF prolyl hydroxylase enzyme; pVHL, von-Hippel Lindau protein; ROS, reactive oxygen species; RTK, receptor tyrosine kinase; TCA, tricarboxylic acid cycle; Ub, ubiquitin; mRNA, messenger RNA.
is ubiquitously expressed, HIF2α is more limited and has been observed in a subset of cell types, including hepatocytes, cardiac myocytes, and endothelial cells. The different phenotypes observed in the HIF1α and HIF2α mice, as well as a number of other studies, strongly suggest that, although each shares a set of genes that they regulate, they also each control the expression of unique target genes. Studies performed in different cell types have shown that HIF2α specifically regulates hypoxic upregulation of gene products including cyclin D1, transforming growth factor α, POU5F1, and matrix metalloproteinase 2, whereas HIF1 regulates a large number of glycolytic enzymes including glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase 1, Bnip3, and carbonic anhydrase 9. Importantly, the precise gene set altered by HIF1 and 2 is tissue specific, as it depends on the prevailing chromatin structure.

HIFs are therefore stabilized rapidly upon the loss of oxygen supply, resulting in a concerted transcriptional response to modulate cellular phenotype. This transcriptional response has wide-ranging effects that are beneficial to ischemic and recently reperfused tissue. As the HIF transcription factors regulate the expression of such a considerable number of genes, they are likely to exert their protective influence on I/R tissues through pleiotropic effects. A large number of upregulated HIF1 target genes are associated with glycolysis and, therefore, permit higher rates of ATP production from glucose, which is an oxygen-independent process. This is important both under ischemic conditions and upon reperfusion as it allows ATP levels to be sustained further into the ischemic episode, as well as permitting rapid ATP production after resumption of the blood supply. For tissues with considerable ATP demand, such as the myocardium, the rapid restoration of ATP generation capacity is key to retaining function post-I/R. Avoiding dependency on oxidative phosphorylation for ATP production after reperfusion is important as many mitochondrial metabolic enzymes can be inhibited or inactivated by the ROS generated by reperfusion, and efficient oxidative metabolism may therefore have to wait for new protein production by the cell. In addition, HIF stabilization also increases the production of angiogenic factors by the tissue, such as vascular endothelial growth factor, which can aid the restoration of an efficient blood supply through the damaged tissue.

HIFs are a central part of PreC and PostC mechanisms

Ischemic PreC (IPC) and ischemic PostC have been shown to be effective in reducing infarct size in a number of models and tissues. Both conditioning protocols use acute cycles of I/R, with the ischemic episode lasting a few minutes. IPC results in a protected phenotype in the tissue that has two phases: one that occurs within minutes and can last a few hours, and another that begins at around 24–48 hours and lasts a number of days. There are several lines of evidence that places HIF as a central mediator of IPC-mediated protection. IPC and PreC protocols have both been demonstrated to elicit HIF1α stabilization and transactivational activity—an effect that was shown in one study to be specifically PHD2 (and not PHD1 or 3) mediated. Evidence from a heart model of IPC in mice also demonstrated that HIF1α mice have reduced IPC-mediated protection from I/R. Indeed, further evidence in a renal ischemic model showed that the inhibition of PHDs and stabilization of HIF1α was sufficient to produce a PreC phenotype. However, the rapidity of induction of the early IPC phase is most likely quicker than a HIF-mediated transcriptional response can be observed. Therefore, it is possible that the upstream oxygen sensors that control HIFs—the PHDs—can induce this biphasic response through direct hydroxylation of as-yet unknown targets. There is also strong evidence to suggest that PHD1 inhibition, which is observed downstream of dimethyloxalylglycine (DMOG) treatment, can produce a strong protective effect in a number of organ systems, which is HIF1α-independent (although it may be HIF2α-dependent). However, considering that PHDs themselves can be directly inactivated by increased cellular ROS levels, as would occur with repeated I/R cycles, both IPC and PostC protocols appear ideal to inactivate these enzymes, thereby altering their capacity to hydroxylate target substrates. It is possible, therefore, that the PHDs themselves may play an important role in protection from I/R injury through the loss of hydroxylation of as-yet unknown substrates to directly and acutely alter cell signaling. The late phase of IPC, although also downstream of PHD signaling, has a profile that is consistent with HIF-mediated protection. Although hypoxia-mediated gene transcription downstream of HIF can be observed within 24 hours, full stabilization of this transcriptome can take up to 48 hours, which is very similar to the profile of the late IPC response.

Interestingly, it appears that HIF1 activation may be key in the remote IPC scenario, where HIF1-mediated upregulation of interleukin-10 as well as stromal cell-derived factor 1 have both been shown as capable of inducing remote IPC in the heart. Interleukin-10 provides protection from I/R injury through activation of AKT signaling during oxygen–glucose
deprivation of cortical neurons, suggesting that this mechanism may be pertinent in a number of different tissues.

The concept of ischemic PostC has received much attention recently due to the potential for ameliorating ischemic damage in patients received into emergency departments after an ischemic incident. PostC is carried out using a series of short I/R cycles immediately upon reperfusion after the original ischemic event. A large number of signaling pathways have been proposed as being involved in this process, including adenosine receptor signaling, alterations in Ca\(^{2+}\) dynamics, and inhibition of the mitochondrial permeability transition pore. Two recent papers reported a role for HIF1\(\alpha\) in the PostC protection phenomenon. In the first, which investigated PostC of the myocardium, PostC was elicited through DMOG-mediated inhibition of the PHDs, thereby stabilizing HIF1\(\alpha\) (and presumably HIF2\(\alpha\)) expression. In the second, a mechanism for sevoflurane-mediated protection from cerebral ischemia was investigated. The authors found a phosphatidylinositol 3-kinase (PI-3K)-dependent effect of sevoflurane on HIF1\(\alpha\) expression, which resulted in increased heme oxygenase 1 mRNA, a HIF1 target gene. However, the data in these papers are also consistent with a HIF1\(\alpha\)-independent mechanism that could be through PHD signaling or other PI-3K targets. Indeed, PI-3K activation has many protective effects on cell viability independently of HIF-1, including through the phosphorylation of the proapoptotic protein BAD and the enzyme glycogen synthase kinase 3\(\beta\). It is worth noting that the demonstration of sevoflurane-mediated protection by Ye et al is part of a growing body of evidence that suggests that the HIF signaling axis is a potential mechanism by which volatile anesthetics can protect from I/R injury. Much more investigation into this area is required in order for efficacious clinically relevant therapeutics to be developed to be used as PostC agents.

**Interplay between adenosine signaling and HIFs**

Signaling by the metabolite adenosine has long been linked to protection from ischemia in the heart, brain, and kidney. Extracellular adenosine is observed as a result of cellular damage, release of adenosine from intracellular sources, or through the breakdown of extracellular adenosine monophosphate (AMP) by 5'-nucleotidases. The increase in adenosine levels observed during ischemia in the myocardium are thought to be due to the relative increase in AMP concentrations due to the action of adenylyl kinase on adenosine diphosphate, producing ATP and AMP. Adenosine is recognized by plasma membrane-spanning adenosine receptors A1, 2A, 2B, and 3 (encoded by ADORA1, 2A, 2B, and 3 genes), all of which are G protein-coupled receptors. Types A1 and A3 are G\(\alpha\)q linked, meaning that their activation leads to a reduction in adenylyl cyclase activity (and therefore cAMP levels) and increased phospholipase C (PLC) activity. PLC action on phosphoinositol-containing lipids produces inositol phosphates and diacylglycerol, both of which signal to downstream effector pathways, which includes the activation of protein kinase C (PKC). Conversely, A2A and B subtypes are coupled to stimulatory G proteins and result in increased cAMP levels and protein kinase A activation. Both subtypes are able to activate MAPK signaling. Adenosine signaling through its receptors has been strongly linked with modification of myocardial function and survival, as well as modulation of I/R injury in a different organs. It was initially shown that adenosine infusion alone or as part of a cardioplegic solution could be used to increase ATP levels during and after short ischemic episodes. However, adenosine was also shown to play a role in myocardial PreC, as treatment with either adenosine or an A1 agonist were shown to recapitulate a bona fide IPC, while an adenosine-receptor antagonist reversed the effect of conventional IPC.

It is likely that some of the protection from I/R injury through the action of HIFs is mediated through the adenosine-mediated signaling cascade. HIF1 has been shown to increase the expression of the extracellular 5'-nucleotidase CD73 during intestinal ischemia, which would be predicted to increase extracellular adenosine concentrations. The authors also showed that a DMOG induced an increase in the A2B receptor that was abolished in HIF1\(\alpha\)\(^{-}\) mice, suggesting that HIF1-dependent protection may be through activation of this receptor (Figure 1). HIF1-dependent induction of A2B has also been observed in vascular endothelial cells, where it was shown to play a role in hypoxia-induced tubule formation as well as barrier protection.

The other stimulatory G protein-linked adenosine receptor, A2A, has been proposed to modulate HIF1 activity. Activation of this receptor in macrophages has been shown to increase HIF1\(\alpha\) expression and HRE binding in normoxic conditions. Using inhibitor studies, the authors suggested that this stabilization was through AKT and PKC\(\delta\) activation downstream of the A2A receptor. Both these kinases have been previously shown to stabilize HIF1\(\alpha\) independently of oxygen tension; AKT activation is known to result in enhanced HIF1\(\alpha\) expression through increased translation and PKC\(\delta\) activation (which could also be downstream of
AKT activation) was shown to increase HIF1 binding to HREs by an as-yet undescribed mechanism.\(^9\) It is possible that the regulation of HIF1α by PKCδ could involve phosphorylation of the same site as MAPKs, which is known to enhance heterodimer formation.\(^9\)

Interestingly, it has been shown that ADORA2A is a HIF2 target gene in pulmonary endothelial cells.\(^2\) Endothelial cells from different sources have been shown to express different levels of the A2A and A2B receptors,\(^2\) and it has been reported that the relative expression of each changes upon induction of hypoxia.\(^4\) However, signaling through A2B and A2A receptors have both been shown to induce angiogenesis.\(^2\) It is also important to note that A2A receptor signaling during ischemia is not always protective; data from cerebral ischemic models suggest that blockade of A2A receptors protects against associated damage in adult rodents.\(^2\) The effect of this on the ischemic stabilization of HIF was not established. Finally, the A3 receptor has also been shown to synergize with hypoxia to induce further stabilization of HIF1α.\(^9\)

It is therefore clear that there is a reciprocal relationship between the HIFs and adenosine receptors that varies with the expression of both the adenosine receptors and HIFα/β subunits. In the majority of cases, it appears that this signaling axis is protective, but with tissue specific outcomes; for example, signaling elicits an angiogenic response in endothelial cells whereas, in the myocardium, it appears to be prosurvival.

## The role of HIFs in the link between circadian rhythm and I/R injury

There has been recent interest in the observation that incidence of cardiovascular events, including myocardial infarctions and stroke, varies with the natural circadian rhythm.\(^9\) Interestingly, the circadian rhythm proteins, and most strikingly Per2, were recently identified as altered in the hearts of mice deficient for the A2B receptor (ADORA2B\(^−/−\)).\(^9\) These mice not only lost the circadian control of Per2, but also lost an IPC-induced increase in Per2 expression. Previous studies have demonstrated that A2B-receptor activation results in MAPK activity, which has been demonstrated to regulate Per2.\(^9\)\(^,\)\(^10\) As the mice also lost the ischemic induction of glycolytic enzymes and lactate production in Per2\(^−/−\) mice, the authors investigated the ischemic stabilization of HIF1α and found that it was abolished.\(^9\) These data introduce a novel and exciting link between adenosine signaling, control of circadian rhythms, and the cellular hypoxic response. Interestingly, there are further links between hypoxia and the control of circadian rhythm that may also play a role in I/R injury as DEC1 (also known as SHARP1 and Stra13), which has been shown to play a role in the regulation of the molecular clock, is strongly induced by hypoxia in a HIF-dependent mechanism.\(^10\)\(^,\)\(^10\) However, the role of DEC1 in I/R injury has not yet been explored.

## Summary – the potential for therapeutic targeting of the HIF axis

Evidence from a number of tissues and in vitro studies suggests that activation of the HIF axis can protect from I/R injury. Therapeutic approaches that target this system, whether directly or indirectly, are likely to have beneficial effects on patient outcomes. Indeed, a number of studies described above support this, and used iron chelators or direct competitive inhibitors of the PHD enzymes to stabilize HIF in models of stroke and renal and myocardial infarction.\(^5\)\(^,\)\(^8\)\(^,\)\(^9\) It is not surprising that there are PHD-inhibiting compounds in both preclinical testing and clinical trials for use in acute ischemia. Interestingly, the use of iron chelators in neurological diseases such as stroke actually predates the discovery of HIFs and PHDs, and were used for their ability to preserve cellular metabolism (reviewed in Karuppagounder et al\(^10\)). Therefore, it would not be unexpected if targets for iron chelators other than the PHDs and HIFs were found that help preserve tissue viability during I/R. Finally, therapies that indirectly target the HIF axis are also likely to aid tissue recovery as part of a multifactorial approach. Activators of AKT or MAPK signaling, such as the use of insulin during surgery, as well as adenosine receptor agonists could be used in combination to increase HIF activity before or during ischemia.

However, we need to understand more about the role of HIFs in I/R injury, in particular in two areas. First, studies are required that dissociate the role of PHD inhibition from HIF activation in I/R injury as it is not yet clear whether HIF is only one (albeit a central) part of the protective effects of PHD inhibition. Second, we need to understand the temporal aspects of modulating this system. Direct effects of PHD inhibition may well be very rapid as their effect is posttranslational, whereas those responses downstream of HIFs can take much longer – even hours – to manifest themselves. It is possible that PHD inhibition can acutely protect tissues, while HIF activation is required post-reperfusion.

Regardless, it is clear that this oxygen-sensing system is central to the protection of tissues from I/R injury, and further work to elucidate the signaling mechanisms surrounding this
phenomenon is likely to lead to better options for therapeutic interventions to improve clinical outcomes.

Acknowledgments

We thank Doctors Giulio Laurenti, David Bartlett, and Gavin McNee for their critical reading of the manuscript and constructive comments.

Disclosure

The authors report no conflicts of interest in this work.

References

Submit your manuscript here: http://www.dovepress.com/hypoxia-journal

Hypoxia is an international, peer-reviewed, open access journal that aims to improve understanding of the biological response to hypoxia. The journal will publish original research articles, reviews, methodological advances, clinical studies, and expert opinions that identify developments in the regulation of the physiological and pathological responses to hypoxia and in the therapeutic targeting of hypoxia-responsive pathways. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

For personal use only.

Hypoxia downloaded from https://www.dovepress.com/ by 54.70.40.11 on 11-Sep-2018

Hypoxia 2014:2

Dovepress

Submit your manuscript here: http://www.dovepress.com/hypoxia-journal

Hypoxia is an international, peer-reviewed, open access journal that aims to improve understanding of the biological response to hypoxia. The journal will publish original research articles, reviews, methodological advances, clinical studies, and expert opinions that identify developments in the regulation of the physiological and pathological responses to hypoxia and in the therapeutic targeting of hypoxia-responsive pathways. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

For personal use only.

Hypoxia downloaded from https://www.dovepress.com/ by 54.70.40.11 on 11-Sep-2018

Hypoxia 2014:2

Dovepress

Submit your manuscript here: http://www.dovepress.com/hypoxia-journal

Hypoxia is an international, peer-reviewed, open access journal that aims to improve understanding of the biological response to hypoxia. The journal will publish original research articles, reviews, methodological advances, clinical studies, and expert opinions that identify developments in the regulation of the physiological and pathological responses to hypoxia and in the therapeutic targeting of hypoxia-responsive pathways. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

For personal use only.

Hypoxia downloaded from https://www.dovepress.com/ by 54.70.40.11 on 11-Sep-2018

Hypoxia 2014:2

Dovepress

Submit your manuscript here: http://www.dovepress.com/hypoxia-journal

Hypoxia is an international, peer-reviewed, open access journal that aims to improve understanding of the biological response to hypoxia. The journal will publish original research articles, reviews, methodological advances, clinical studies, and expert opinions that identify developments in the regulation of the physiological and pathological responses to hypoxia and in the therapeutic targeting of hypoxia-responsive pathways. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

For personal use only.

Hypoxia downloaded from https://www.dovepress.com/ by 54.70.40.11 on 11-Sep-2018

Hypoxia 2014:2

Dovepress

Submit your manuscript here: http://www.dovepress.com/hypoxia-journal

Hypoxia is an international, peer-reviewed, open access journal that aims to improve understanding of the biological response to hypoxia. The journal will publish original research articles, reviews, methodological advances, clinical studies, and expert opinions that identify developments in the regulation of the physiological and pathological responses to hypoxia and in the therapeutic targeting of hypoxia-responsive pathways. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

For personal use only.

Hypoxia downloaded from https://www.dovepress.com/ by 54.70.40.11 on 11-Sep-2018

Hypoxia 2014:2

Dovepress

Submit your manuscript here: http://www.dovepress.com/hypoxia-journal

Hypoxia is an international, peer-reviewed, open access journal that aims to improve understanding of the biological response to hypoxia. The journal will publish original research articles, reviews, methodological advances, clinical studies, and expert opinions that identify developments in the regulation of the physiological and pathological responses to hypoxia and in the therapeutic targeting of hypoxia-responsive pathways. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

For personal use only.

Hypoxia downloaded from https://www.dovepress.com/ by 54.70.40.11 on 11-Sep-2018

Hypoxia 2014:2

Dovepress

Submit your manuscript here: http://www.dovepress.com/hypoxia-journal

Hypoxia is an international, peer-reviewed, open access journal that aims to improve understanding of the biological response to hypoxia. The journal will publish original research articles, reviews, methodological advances, clinical studies, and expert opinions that identify developments in the regulation of the physiological and pathological responses to hypoxia and in the therapeutic targeting of hypoxia-responsive pathways. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

For personal use only.